Citations

Clear

912 citation(s) found for "Yu, Caroline".

Physiologic Transition During Delayed Cord Clamping With Assisted Ventilation in Preterm Infants
Fang, Jennifer L. , Petroni, Gina R. , Law, Brenda Hiu Yan , Gorman, Terri, Leone, Tina A. , Thomas, Sumesh , Niermeyer, Susan, Kattwinkel, John, Duda, Gina M, Petroni, Gina R. , Varhegyi, Nikole, Thielen, Monika, Chisholm, Christian A., Liedl, Lavonne M., Amsbaugh, Amy, Niermeyer, Susan, Barry, John-S, Lamprecht, Amy, Berlinski, Carolyn S, Johnson, Jacque-Lynne F, Irvine, Leigh , Ciorogariu-Ivan, Anna-Maria, Byrne, Bobbi J., Underwood, Mark A. , Poulain, Francis R., Pesavento, Rosa R, Fray, Caroline , Athaide, Melba, Kane, Andrea F., Carlo, Waldemar A., Bulas, Dorothy , Fairchild, Karen D. , Strand, Marya L. , Warren, Jamie B. , Niermeyer, Susan, Niermeyer, Susan, Barry, James A, Rincon, Monica P. , Josephsen, Justin , Hawkins, Melissa, Ciorogariu‐Ivan, Anna‐Maria, Travers, Colm P. , Carlo, Waldemar A. , Kline‐Fath, Beth M. , Epelman, Mónica

Mayo Clinic

JAMA Network Open | November 24, 2025 | Volume: 8 | Issue: 11 | Pages: e2545258

10.1001/jamanetworkopen.2025.45258 | PMID 41284295 Get It

Importance Assisted ventilation during delayed cord clamping (DCC) may improve the physiologic transition of extremely preterm infants immediately after birth. Objective To determine whether assisted ventilation during 120 seconds of DCC was associated with reduced higher-level resuscitative interventions (intubation, chest compressions, or epinephrine administration) compared with DCC for 30 to 60 seconds followed by resuscitation. Design, Setting, and Participants This was a secondary analysis of the VentFirst randomized clinical trial that was conducted from September 2, 2016, through February 21, 2023, at 12 centers in the US and Canada. Infants born at 23 weeks 0 days’ to 28 weeks 6 days’ gestational age (GA) were included. Intervention Infants randomized to the intervention received either positive-pressure ventilation or continuous positive airway pressure from 30 to 120 seconds after birth, followed by umbilical cord clamping. Those randomized to control received 30 to 60 seconds of DCC followed by assisted ventilation. Main Outcomes and Measures The main outcome was the odds of higher-level resuscitative interventions in the delivery room (DR). Intention-to-treat analyses within 2 a priori cohorts (infants breathing well and not breathing well 30 seconds after birth) used the Cochran-Mantel-Haenszel method to estimate the odds ratios (ORs) of intervention vs control. Results All 570 infants enrolled in the trial were included. Infants had a median (IQR) GA of 26.6 (25.2-27.9) weeks and 273 (47.9%) were female. A total of 271 infants (47.5%) were assessed as not breathing well 30 seconds after birth (150 intervention and 121 control), and 299 (52.5%) were assessed as breathing well 30 seconds after birth (128 intervention and 171 control). In the not-breathing-well cohort, 146 infants (53.9%) were intubated in the DR, 4 received chest compressions (2 intervention and 2 control), and 1 received epinephrine (control). Intubation was less frequent in the intervention group (71 infants [47.3%] vs 75 infants [62.0%]; OR, 0.52; 95% CI, 0.30-0.89). When adjusted by GA strata at randomization, infants in the 26 to 28 weeks’ GA stratum who were in the intervention group were less likely to be intubated in the DR (18 of 79 infants [22.8%] vs 29 of 60 infants [48.3%]; OR, 0.32; 95% CI, 0.15-0.65). However, there was no difference in intubation rates for infants in the 23 to 25 weeks’ GA stratum (53 of 71 infants [74.7%] vs 46 of 61 infants [75.4%]; OR, 0.96; 95% CI, 0.44-2.12). Among infants breathing well at 30 seconds, 74 (24.7%) were intubated in the DR, and none received compressions or epinephrine. Intubation rates were similar between intervention and control in the breathing-well cohort. Conclusions and Relevance While the VentFirst trial did not find a difference in death or intraventricular hemorrhage, this secondary analysis found that assisted ventilation during DCC was associated with less intubation in the DR, primarily among infants born at 26 to 28 weeks’ gestation who were not breathing well 30 seconds after birth. Additional studies are needed before implementing assisted ventilation during DCC in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02742454
Neurodevelopmental effects of genetic frontotemporal dementia mutations revealed by total intracranial volume differences
So, Isis , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Swieten, John C. van, Jiskoot, Lize C, Laforce, Robert, Graff, Caroline , Galimberti, Daniela , Vandenberghe, Rik, Xiong, Chengjie , Sorbi, Sandro, Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Masellis, Mario, Moreno, Fermín , Borroni, Barbara , Kolander, Tyler, Mester, Carly , Brushaber, Danielle , Kantarci, Kejal , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J., Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI), Bocchetta, Martina , Jiskoot, Lize C. , Galimberti, Daniela , de Mendonça, Alexandre , Tartaglia, Maria Carmela , Rowe, James B , Synofzik, Matthis , Mester, Carly , Finger, Elizabeth C. , Kantarci, Kejal , Xiong, Chengjie , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Borroni, Barbara , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Sorbi, Sandro , Otto, Markus , Pasquier, Florence , Ber, Isabelle Le , Rowe, James B. , Synofzik, Matthis , Rohrer, Jonathan D. , Boeve, Bradley F. , Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI)

Mayo Clinic

Journal of Alzheimer’s Disease | November 19, 2025 | Volume: 109 | Issue: 1 | Pages: 278-290

10.1177/13872877251393414 | PMID 41259271 Get It

Background Converging evidence hints at neurodevelopmental effects in people at risk of genetic frontotemporal dementia (FTD). Objective We investigated total intracranial volume (TIV), a neuroimaging marker of neurodevelopment, and years of education differences between adult mutation carriers and familial non-mutation carriers, as measures of the structural and functional neurodevelopmental effects of FTD-causing genetic mutations. Methods This cross-sectional cohort study, facilitated through the FTD Prevention Initiative (FPI), included 902 adult pathogenic mutation carriers of GRN , MAPT , or C9orf72 , and 532 familial non-carriers. ANCOVAs were computed to compare TIV and education between groups per gene. Pearson's correlations were used to examine associations between TIV and education. Results Mutation carriers (mean ± SD age = 50.0 ± 13.2 years, sex = 55% female, n ( GRN ) = 298, n( MAPT ) = 187, n ( C9orf72 ) = 417) were compared to familial non-carriers (age = 48.0 ± 12.9 years, sex = 58% female, n ( GRN ) = 201, n( MAPT ) = 114), n ( C9orf72 ) = 217). Consistent with prior findings in young adults, GRN carriers showed larger TIV, on average by 20531 mm 3 , compared to familial non-carriers (95% CI [85.4, 40977], p = 0.049, η 2 p = 0.008). Larger TIV correlated with higher years of education in GRN carriers (95% CI [0.01, 0.24], r (295) = 0.12, p = 0.03) and GRN non-carriers (95% CI [0.08, 0.34], r(198) = 0.21, p = 0.002). MAPT carriers demonstrated smaller TIV than non-carriers, on average by 29896 mm 3 (95% CI [–58248, −1545], p = 0.039, η 2 p = 0.02). Models with C9orf72 and education as outcome variables did not reveal significant differences. Conclusions In support of the neurodevelopmental hypothesis of FTD, GRN and MAPT mutations are linked to structural neurodevelopmental changes in TIV. Further research is needed to identify mechanisms underlying neurodevelopmental influences of FTD mutations and ascertain their suitability as intervention targets.
International Reference Values for Surgical Outcomes of Total Pancreatectomy
Berchtold, Caroline , Kuemmerli, Christoph, Li, Zhihao , Eden, Janina , Wu, Pengfei , Cecchetto, Sara Nicole, Kendrick, Michael L. , Pecorelli, Nicolò , Guarneri, Giovanni , Farooqui, Waqas , Tschuor, Christoph , Burgdorf, Stefan Kobbelgaard , Mühlhäusser, Julia , Gass, Jörn‐Markus , Koh, Ye-Xin, Seip, Tomas, Santibañes, Martín de , Todeschini, Letizia , Marchegiani, Giovanni, Belfil, Nadiya , Boggi, Ugo, Cappelle, Marie , Koerkamp, Bas Groot , Dutkowski, Philipp , Hackert, Thilo , Truty, Mark J. , Group, Outcomes for Total Pancreatectomy, Valle, Valentina , Giulianotti, Pier Cristoforo , Pessaux, Patrick, Thapa, Prabin , Kuzman, Matta , Pandanaboyana, Sanjay, He, Jin , Kendrick, Michael, Truty, Mark, Li, Zhihao , Groot Koerkamp, Bas , Müller, Philip C , Breuer, Eva , Vallorani, Alessia , Hansen, Carsten Palnæs , Guidetti, Cristiano , Campbell, Brady A. , Cecchetto, Sara Nicole, Gudmundsdottir, Hallbera , Starlinger, Patrick , Goh, Brian K P , Koh, Ye-Xin , Rebelo, Artur , Kleeff, Jorg H. , Marchegiani, Giovanni , Lesurtel, Mickaël , Machado, Marcel Autran C. , Kauffmann, Emanuele F. , Benedetto, Fabrizio Di , Roberts, Keith John , Nevler, Avinoam , Lavu, Harish , Nickel, Felix , He, Jing , Falconi, Massimo , Billeter, Adrian T. , Müller-Stich, Beat Peter , Group, Outcomes for Total Pancreatectomy, Halle-Smith, James Michael , Giannone, Fabio , Pessaux, Patrick , Sánchez‐Velázquez, Patricia , Maharjan, Dhiresh Kumar , Torres, Orlando Jorge Martins

Mayo Clinic

JAMA Surgery | November 12, 2025 | Volume: 161 | Issue: 1 | Pages: 50

10.1001/jamasurg.2025.4941 | PMID 41222926 Get It

Importance Total pancreatectomy (TP) is indicated for advanced pancreatic cancer or multifocal tumors. Furthermore, TP may be performed to avoid the risk of pancreatic fistula in selected patients to improve the perioperative risk profile. Objective To define reference values for TP based on a low-risk cohort treated at expert centers. Design, Setting, and Participants This multicenter study analyzed outcomes from patients undergoing primary TP for malignant or benign lesions from 25 international expert centers from January 2017 to November 2023. Low-risk patients undergoing TP (LR-TP) were without vascular resections or significant comorbidities. Exposures TP. Main Outcomes and Measures Twenty reference values were derived from the 75th or the 25th percentile of the median values of all centers. Outcomes of LR-TP were compared with a cohort of TP with vascular resection, TP due to high-risk pancreatic anastomosis, and the benchmark values for low-risk pancreatoduodenectomy. Results Of 994 patients, 333 (33.5%; median [IQR] age, 66 [58-72] years; 171 male [51.4%]) qualified as the LR-TP cohort. Reference values included blood loss (≤1000 mL), major complications (≤37%), 3-month postoperative mortality (<6%), and retrieved lymph nodes (≥29). Compared with TP with vascular resections, reference cutoffs were not met for major complications (51% vs LR-TP ≤37%) and 90-day mortality (11% vs LR-TP ≤6%). For TP due to high-risk anastomosis, failure to rescue rate (38% vs ≤6%) and 90-day mortality (11% vs LR-TP ≤6%) were not met. Compared with pancreatoduodenectomy, reference values for postoperative mortality were 3 times higher for LR-TP (≤2% vs ≤6%) and less for resected lymph nodes (≥16 vs ≥29). Conclusions and Relevance This case-control study provided global reference values for TP, indicating significantly higher postoperative morbidity and mortality compared with pancreatoduodenectomy. Perioperative morbidity of TP was especially increased in patients with vascular resections. These reference values can serve for quality control of pancreatic surgery.
CTNI-63. PRELIMINARY SAFETY AND EFFICACY OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS
Nayak, Lakshmi , Nowakowski, Grzegorz S. , MD, Adolfo De La Fuente,, Levi, Itai, Lavie, David, Castellino, Alessia , Geethakumari, Praveen Ramakrishnan , Schenone, Laurence , Ferreri, Andrés J.M. , Nassi, Luca, Hernandez‐Ilizaliturri, Francisco J. , Chauhan, Amrita , Lane, Maureen, Zhou, Li , Zhao, Wanying, BS, Dora Ferrari,, Vose, Julie, D’Angelo, Christopher R, Dąbrowska‐Iwanicka, Anna , Tun, Han W. , Moustafa, Muhamad Alhaj , MD, Adolfo De La Fuente,, Grommes, Christian , Taszner, Michał , Calimeri, Teresa , Houillier, Caroline , MD, Anna Schmitt,, Lane, Maureen E., BS, Dora Ferrari,

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v141-v141

10.1093/neuonc/noaf201.0559 Get It

Abstract There are no approved treatments for relapsed/refractory (R/R) PCNSL. We show promising efficacy in the salvage setting using emavusertib in combination with ibrutinib, which targets the BCR and TLR pathways. These 2 major pathways are associated with activation of NF-κB. Updated safety and efficacy data of this combination in R/R PCNSL from the ongoing Phase 1/2 TakeAim Lymphoma trial (NCT03328078) will be presented. As of 01 May 2025, 33 patients with R/R PCNSL were treated with emavusertib in combination with ibrutinib. Eligible patients receive emavusertib in combination with ibrutinib until tumor progression or unacceptable toxicity. Median age was 63 years (range 43-81); 16 patients were male. Median prior anti-cancer therapy was 2 (range 1-5); 26 (78.8%) patients had prior BTKi exposure. Median duration of emavusertib/ibrutinib treatment was 51 days (range 5-798). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 11 (33.3%) patients; neutropenia in 5 (15.2%) patients, amylase increased, lipase increased, and leukopenia in 2 (6.1%) patients each. The majority of Grade ≥ 3 TRAEs were reversible and manageable. Among the 19 BTKi-experienced patients treated for ≥ 28 days, there were 5 CRs and 2 PRs, with an ORR of 36.8%. Three patients with CR were on treatment for 10+ mos, with 1 CR patient ongoing with DOT of 26.2+ mos. Among the 5 BTKi-naïve patients treated for ≥ 28 days, 1 achieved CR and 3 had PR, with ORR of 80%; the CR patient is ongoing with DOT of 18.1+ mos. The ORR in the combined population was 45.8% (6 CRs; 5 PRs). The combination of emavusertib and ibrutinib demonstrates promising clinical activity and an acceptable safety profile in patients with R/R PCNSL. This regimen appears capable of overcoming resistance to prior BTKi therapy. Patient enrollment in this trial continues.
CTNI-59. ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION
D’Angelo, Christopher R, MD, Adolfo De La Fuente,, Levi, Itai, Nayak, Lakshmi , Lavie, David, Castellino, Alessia , Geethakumari, Praveen Ramakrishnan , Schenone, Laurence , Ferreri, Andrés J.M. , Nassi, Luca, Schmitt, Anna , Lane, Maureen, Zhao, Wanying, Nowakowski, Grzegorz S. , Grommes, Christian , Dąbrowska‐Iwanicka, Anna , Tun, Han W. , MD, Adolfo De La Fuente,, Taszner, Michał , Calimeri, Teresa , Houillier, Caroline , Lane, Maureen E.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v140-v140

10.1093/neuonc/noaf201.0555 Get It

Abstract PCNSL is a rare and aggressive NHL with no approved treatments for R/R patients, representing a critical unmet need. MyD88 mutations in ~70% of PCNSL patients drive IRAK4 activation, promoting NF-κB signaling, inflammation, and tumor progression. Emavusertib, a potent oral IRAK4 inhibitor, crosses the blood-brain barrier and shows preclinical synergy with BTKis, and has the ability to re-sensitize BTKi-resistant cell lines. This study evaluates the molecular and PK data associated with responses to emavusertib + ibrutinib combination therapy in R/R PCNSL patients. The safety, clinical activity, and potential biomarkers of emavusertib in R/R PCNSL are being investigated in the ongoing TakeAim Lymphoma trial (NCT03328078). Pre-dose and 1.5-hour post-dose plasma samples were collected on Day 1 of Cycles 3, 5, and 7. CSF samples were obtained via a lumbar puncture within 1.5 hrs of collection of the post-dose plasma PK sample on Cycle 3 Day 1. As of 06 December 2024, CSF concentration was available for 7 patients. The mean emavusertib concentration in CSF was 81.3 ng/ml (54.7-104.0) in patients receiving 100 mg emavusertib BID (n=4). In patients receiving 200 mg emavusertib BID (n=3), the mean emavusertib concentration in CSF was higher at 175.7 ng/ml (114.8-209.4), which is 2.2 × the mean value in patients who received 100 mg emavusertib BID (p-value = 0.02). MyD88 mutation status was available for 7 patients of which all had prior BTKi exposure. Among these patients, 6 had MyD88 mutations of which 4 had responded (3 CRs and 1 PR) to the combination with DOR up to 18.9 mos with data collection ongoing. Preliminary CNS PK data demonstrate that emavusertib concentration in CSF increases with increasing emavusertib dose. Patients with MyD88 mutations showed expected promising preliminary efficacy to emavusertib + ibrutinib combination and may overcome BTKi resistance. Enrollment is ongoing.
RADT-33. PROGNOSTIC AND PREDICTIVE EFFECT OF AGE IN MOLECULARLY-DEFINED LOWER GRADE GLIOMAS: A REPORT FROM THE PROSPECTIVE GLIOMA RESEARCH (PROGRES) DATABASE
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A., Mercurio, Ann, Siegelin, Markus D. , Touat, Mehdi, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter , Neugut, Alfred I. , Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Kocakavuk, Emre , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Ducray, François , Dehais, Caroline , Grinband, Jack , Yu, James , Walch, Henry , Parker, Mitchell I , Gallitto, Matthew , McKhann, Guy M. , Ostrom, Quinn T. , Pike, Luke R G , IWAMOTO, FABIO MASSAITI , Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v99-v100

10.1093/neuonc/noaf201.0403 Get It

Abstract PURPOSE Age over 40 years is commonly regarded as a “high risk” feature and potential indication for adjuvant chemoradiotherapy for patients with lower grade glioma in most clinical practice guidelines. However, these recommendations are based on retrospective observations and their subsequent incorporation into legacy clinical trials. It is unclear whether age remains a relevant prognostic factor in the molecular era. METHODS The Prospective Gliomas Research [PROGRES] Database contains individual patient-level data from 11 prospective clinical trials or observational registries, including seven international trials from the RTOG, EORTC, or Alliance cooperative groups. We determined the association of age with progression-free survival (PFS) in low grade or anaplastic glioma, stratified by isocitrate dehydrogenase (IDH1/2) status. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] Database). RESULTS We identified 1,619 and 1,271 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH-wildtype tumors were more common in patients >40 years (38% vs, 5%, odds ratio: 11.3 [95%CI 6.5 – 19.7]). Age was associated with PFS in IDH-wildtype (5-year PFS: 6% vs, 24%, P =.003) but not in IDH-mutant glioma (60% vs, 59%, P = 0.22, P value of interaction <.001). In IDH-wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% vs, 28%), EGFR amplification (41% vs, 15%), and chromosome +7/-10 alteration (57% vs, 25%). Age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone in IDH-mutant glioma. CONCLUSION Older age is a putative surrogate for IDH-wildtype status, but was not an independent predictor of progression in IDH-mutant lower grade glioma and did not predict benefit from chemoradiotherapy. In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.
Evaluation of Interventions for Cognitive Symptoms in Long COVID
Koltai, Deborah, Laskowitz, Daniel T. , Wisnivesky, Juan P., Federman, Alex D. , Silverstein, Adam M. , Lokhnygina, Yuliya, Haddad, Michelle M., Mahncke, Henry W. , Vleet, Tom Van, Huang, Rong , Cox, Wendy C., Terry, Diana, Karwowski, Jeannie, McCray, Netia, Lin, Jenny , Singh, Upinder , Geng, Linda N. , Reece, Rebecca , Moy, James N., Arvanitakis, Zoe , Parthasarathy, Sairam , Patterson, Thomas F., Gupta, Aditi , Parsonnet, Jeffrey, Kiriakopoulos, Elaine T. , Mullington, Janet , Jolley, Sarah E. , Shah, Nirav S. , Morimoto, Sarah Shizuko , Lee‐Iannotti, Joyce , Isache, Carmen, Frontera, Jennifer , O’Steen, Ashley, James, Melissa, Harper, Barrie, Zimmerman, Kanecia O. , Lawler, Andrew , Johnson, Brandon M. , Pitsch, Chloe E. , Feuerriegel, Elen , McKeehan, Jeffrey, Molden, Joie, Reid, Kayleigh M., Dowling, Sarah , Wodushek, Thomas, Canton, Diara, Turut, Dilara, Sheppard, Ethan , Scott‐Sutherland, Jennifer, Shaughnessy, Lynn, Beck, Michelle L. , Heisey, Sabrina, Katragadda, Vaishanvi, Yusuff, Amidat, Perlack, Amy, Merisme, Christie, Krause, David, Schulte, Duncan, Dupre, Fabiola, Sanchez, Gina A. Montealegre , Asupoto, Olanike, Simmons, Quinneil, Schroeder, Ryan W. , Timlin, Shannon, Devis, Ycar, Carter, Della, Caceres, Leomaris Caba, Rodríguez, Miguel Grande, Alvarez, Zariya , Yakubov, Amin , Engelson, Celia, Reyes, Michael, Youkhana, Alvin, Jennings, Cheryl , Naquiallah, Dina, Behun, Dylan , Stephen, Ellen, Timm, Emily , Bilimoria, Farrah, Li, Grace , Stricker, Thomas, Michelle, Kang, Minnie, Suarez, Rebeca Tojo, Carmona, Tania, Ramírez, Ana, Kadubek, Grace, Baker, Aileen, Romo-Serna, Andrea, Predki, Barbara, Leman, Cindy, Panhans, Cristina, Roth, Genevieve E., Rudraraju, Gowrisree , Miller, Hannah , DeLisa, Julie A., Williams, Kat, Woodson, Kimberly S., Jennette, Kyle J. , Villanueva, Laura, Norwick, Maria, Martínez, M. T., Rowley, Matt, Carrithers, Michael D. , Pliskin, Neil H. , Pérez, Nicolás , Durkin, Nicole M., Maniar, Nikita, Beety, Rachel, Daspgupta, Raktima, Ramchandran, Ramaswamy, Jaramillo, R., Hasek, Sharon, Macías, S Aguirre, Schuh, Tina , Ialacci, Sarah, Bailey, Christopher , Labbato, Danielle, Hautmann, Amanda , Smith, Beth, Nath, Dia, Meyer, Jessica , DiFrancesco, Kathryn, Pettinato, Kimberly, Curtis, Lynette, Daher, Joviane , Koberssy, Ziad , Mavar, Caleb, Andrefsky, John, Merheb, Alexander, Hernandez, Carla, Baissary, Jhony , Atieh, Ornina , Pereira, Carol, Carpenter, Deborah, Raynor, Jennifer , Brunton, Kristine, Podgoreanu, Andreea, Bunch, P. C., O’Brien, Sean M. , Dickey, Sheila, McNulty, Steven E., Gajjar, Varsha, Neale, Alec C. , Cohen, Cari, Geary, Elizabeth, Campanella, Franco, Anderson, Kirsten, Prestige, Laura, Guidotti-Breting, Leslie, Biewer, Megan, Morton, Melissa , Mathenia, Nicholas, Adeyemi, Oluwadamilola A. , Hengst, Samanike, Ning, Wei , Vanderloo, Adam, Caplan, Amanda, Chen, July, Acree, Mary Ellen , Nakhate, Mukund, Dan, Zaw Nu, Pk, Switzer, Aryal, Shambhu , Sanchez, Jessica, Sims, Luke, Ferdinand, Rebecca , Mammadova, Mehriban, Grimes, Carolyn Z. , Vidales, Elizabeth, Pham, Hau , Nielsen, Laura, Keller, Maryjane, Uruba, Syeda, Hernandez, Maria, Patel, Bela , Umana-Sanchez, Virginia, Pak, Chong, Gainer, Jeffery, BURR, R, Trapuzzano, Ashleigh, Celso, Brian G. , Bienkowski, Grace, Bowman, Jennifer, Verdecia, Jorge , Zerwekh, Kathryn, Serrano, Liliana , Marotz, Meghan, Propp, Piper, Sarig, Yonatan , Murphy, Annie, Comfort, Brandon, Torres, Iri, Klein, Jeffrey A. , Walker, John, Moore, John J., Tempest-Browning, Lisa, Arain, Mudassar, Kemp, Pamela, Sullivan, Samantha, Way, Sonja, Chevalier, Jessica, Sykes, Carly, Kruck, Carrie L., Sackett, L. W., Bang, Claire, Hynes, Mary, Gallagher, Torrey L., Childers-Kakos, Margaret, Zia, Ahmad, South, AP, Oravets, Anne, Ferreyra, Carolyn, Glaze, Chad, Villanueva, Daphne-Dominique , Blystone, Erica, Pritchard, Jane, Alyward, Laura, Cooper, Melissa, Chidester, Michelle, Alderson, R. Matt , Clark, Renee D., Hodder, Sally , Sarwari, Arif R, Juskowich, Joy, Welch, Shelly, Civil, Alyssa, Bendl, Ashley, Dicker, Elisa, Hanson, Hannah, Viola, Heather, Morinigo, Janice, Pantaleon, Karisma, Marcon, Kathryn, Stone, Kimberly, Stewart, Kiwan, Evo-Ortega, Lorraine, McVeety, Megan, Guliyeva, Sabina , Watson, Eric , Pehel, Shayna, Ko, Tim, Caropolo, Leah, Kocas, H. Deniz , O’Donnell, Andrew, Saperia, Corey , Thai, Daniel, Pathak, Divya , Keller, Jennifer M. , Olszewski, Kelly, Clinton, Kimberly, Cherian, Kirsten , Dutton, L M, Elepano, Ma, Mohapatra, Sukanya , Chen, Ting , Wroolie, Tonita, Leang, Zenita, Shashidhar, Sumana, Nguyen, T L, Ravisankar, Ashwath, Weiden, Brycie, Bolliger, Dawn, Glesne, Heather, Dixon, Jennifer , Chebrolu, Praneeth, Gazali, Zarine, Hurst, Whitney, Fry, Avery, Murthy, Ganesh, Grischo, Garrett, Erickson, Heidi L. , Gomez, Isaias, Copeland, Jacquelynn, Galaz, Judy, Autry, Lynn, DiLise-Russo, Marjorie, Marshell, Nikki, Borwege, Sabine, Vadovicky, Sheila, Marsh, Stephanie, Hartley, William, Murtagh, Linda, Kennedy, Anna, Meltzer-Christensen, Annie, Stringham, Caitlyn, Gaskin, Ella, Judd, Melissa, Côté, Sarah , Mahasenan, Shreya, Bjorklund, Todd, Farner, Cheryl E., Taylor, Barbara S. , Soileau, Bridgette, Cote, Cyrena , Hromas, Gabrielle A., Scholler, Irma, Longoria, Lisa, Heard, Patricia, Jones, Johnnie, Tragus, Robin , Harris, Maya, Pinones, Alexis, Anderson, Alyssa , Hastings, Gabrielyd, Courtright, jessica, Jayakumar, Madhumita, Fischer, M, Solis, Pamela, Harteloo, Alex, Elias-Warren, Anna, Nguyen, Daniel , McDonald, Dylan , Rau, Holly , Mernaugh, Jean, Pagulayan, Kathleen F. , Watanabe, Kino, Huden, Kristen, Peabody, Laurel, Mei, Tiffany, Ogunwuyi, Catherine, Cobbina, Esther, Sankar, Ian, Nguyen, Lisa , Fromm, N., Arnold, R. Douglas, Ogu, Stephanie, Yuan, Ying , Ibrahim, Homam , Szum, Izabella, Patel, Jignesh, Sultan, Sonia, Jazayeri, Yasmin, Anderson, Betty Lise, Muñoz, Isabel , Rhys, Logan, Vane, Ryan, Kim, Jessica , Diaz, Leticia M., Yee, Nathan, Gruhn, Robert, Browngoetz, Sarah, Johnson, Elisha, Chand, Arista , Bottrill, Kenneth , Henderson, Kymberly, Johnson, DeArmond, Richard C., Hughes, Trina, Silverstein, A , Silverstein, Adam P , Frontera, Jennifer , Geng, Linda N. , Knopman, David S. , Becker, Jacqueline , Charvet, Leigh , Pilloni, Giuseppina , Huang, Rong, Cox, Wendy, Karwowski, Jeannie, McComsey, Grace A. , Chu, Helen Y. , Ostrosky‐Zeichner, Luis , Fong, Tamara G. , Killgore, William D. S. , Dwyer, Brigid C. , Stringer, William W. , Krishnan, Jerry A , James, Melissa, Johnson, Brandon, Erlandson, Kristine M. , Dowling, Sarah, Hauser, Kristine , Doyle, Michael, Beck, Michelle, Tran, Anh, Altaras, Caroline , Sanchez, Gina, Krengel, Maxine , Ly, Monica T. , Asupoto, Olanike, Schroeder, Ryan, Rodriguez, Miguel, González, David Andrés , Torres, Jimena, García, Maria Luisa , Carrera, Laura, Rutherford, Melissa, Perez, Nicolas, Jaramillo, Ruthie, Smith, Beth, Walkup, Kevin, Scott, Sarah , Mavar, Caleb B., Carpenter, Deborah, Bunch, Pyper, Brown, Richard, Escobar, Carolina, Campanella, Franco, Mathenia, Nicholas, Glickman, Michael S. , Sims, Luke A., Pham, Hoai Phuang, Lopez, John, Hernandez, Maria, Lin, Matthew Junda , Gainer, Jeffery, Brown, Gina , Klein, Jeffrey, Reed, Jessica, Walker, John, Sackett, Lisa, Kaden, Sarah J. , Childers-Kakos, Margaret G, South, Amy, Blystone, Erica, Cooper, Melissa, Alderson, Rachael, Clark, Renee, Bardes, James M. , Hanson, Hannah, Loizos, Maria , Caropolo, Leah J., Fernandez, Luis, Keller, Jennifer, Lin, Rebecca, Brown, Daniel, Dixon, Jennifer, James, Michelle, Kala, Mrinalini , Smith, Ryan S. , Mahasenan, Shreya, Johnson, Hillary, Anderson, Alyssa, Hernandez, Jessica, Sullivan, Michael, Nguyen, Helen , Logue, Jennifer, Mei, Tiffany, Arnold, Rowan, Szum, Izabella , Hatlen, Timothy J. , Anderson, Betty, Munoz, Isabel, Wright, Matthew, Diaz, Leticia, DeCato, Thomas W. , Ortiz, Ernesto, Hildebrand, Lindsey L. , DeArmond, Richard

Mayo Clinic

JAMA Neurology | November 10, 2025 | Volume: 83 | Issue: 1 | Pages: 49

10.1001/jamaneurol.2025.4415 | PMID 41212544 Get It

Importance Treatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need. Objective To test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID. Design, Setting, and Participants This was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID. Interventions Participants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks. Main Outcomes and Measures Cognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days. Results A total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, −0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions. Conclusions and Relevance This phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID. Trial Registration ClinicalTrials.gov Identifier: NCT05965739 .
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
Zhang, Ting , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Katta, Shilpa, Li, Shengchao A. , Wang, Jiahui , Antwi, Samuel O. , Bracci, Paige M. , Du, Mengmeng, Gallinger, Steven , Goodman, Phyllis J. , Katzke, Verena, Patel, Alpa V. , Visvanathan, Kala , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E. , Chanock, Stephen J., Chen, Yu , Giovannucci, Edward L. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A., Jones, Miranda R. , Kraft, Peter, Kurtz, Robert C. , Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Rabe, Kari G. , Rothman, Nathaniel , Sesso, Howard D. , Yuan, Chen, Wolpin, Brian M. , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Li, Shengchao A , Antwi, Samuel O , Arslan, Alan A , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Goodman, Phyllis J , Katzke, Verena , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Perdomo, Sandra , Shu, Xiao-Ou , Visvanathan, Kala , Van Den Eeden, Stephen K , White, Emily E. , Zheng, Wei , Albanes, Demetrius , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E , Chanock, Stephen Jacob , Chen, Yu , Darst, Burcu F , Ferrari, Pietro , Giovannucci, Edward L , Goggins, Michael G , Haiman, Christopher A , Hassan, Manal M , Hung, Rayjean J , Jones, Miranda R , Kraft, Peter , Malats, Nuria , Moore, Steven C , Ng, Kimmie , Oberg, Ann L , Orlow, Irene , Peters, Ulrike , Porta, Miquel , Chaffee, Kari G. , Sánchez, Maria-Jose , Sesso, Howard D , Southey, Melissa C , Um, Caroline Y , Yarmolinsky, James , Yu, Herbert , Yuan, Chen , Zhong, Jun , Wolpin, Brian M , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Yu, Kai , Zhang, Haoyu , Stolzenberg-Solomon, Rachael , Zhang, Ting , Hua, Xing , Arslan, Alan A. , Freeman, Laura E. Beane , Canzian, Federico , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Darst, Burcu F. , Goggins, Michael , Hung, Rayjean J. , Malats, Núria , Moore, Steven C. , Orlow, Irene , Porta, Miquel , Sánchez, María‐José , Silverman, Debra T. , Southey, Melissa C. , Um, Caroline Y. , Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 8, 2025 | Volume: 118 | Issue: 3 | Pages: 437-447

10.1093/jnci/djaf308 | PMID 41206949 Get It

Abstract Background The associations between different types of diabetes, characterized by distinct pathophysiology and genetic architecture, and pancreatic ductal adenocarcinoma (PDAC) risk are not understood. Methods We investigated associations of genetic susceptibility to type 2 diabetes (T2D), 8 T2D mechanistic clusters, type 1 diabetes (T1D), and maturity-onset diabetes of the young (MODY) with PDAC risk. We used genome-wide association study (GWAS) summary-level statistics for T2D (242 283 cases, 1 569 734 controls), T1D (18 942 cases, 501 638 controls), and PDAC (10 244 cases and 360 535 controls) in individuals of European ancestry. Results Two-sample Mendelian randomization (MR) using the Robust Adjusted Profile Score (MR-RAPS) method indicated that genetically predicted T2D was associated with PDAC risk (OR = 1.10; 95% CI = 1.05 to 1.15), particularly the T2D obesity (OR = 1.28; 95% CI = 1.15 to 1.42) and lipodystrophy (OR = 1.25; 95% CI = 1.03 to 1.51) clusters. No association was observed for T1D with PDAC risk (OR = 1.01; 95% CI = 0.99 to 1.02). Pathway/gene-set analysis using the summary-based Adaptive Rank Truncated Product (sARTP) method revealed a significant association between the MODY gene-sets and PDAC risk (P = 1.5 × 10−8), which remained after excluding 20 known PDAC GWAS loci (P = 7.6 × 10−4). HNF1A, FOXA3, and HNF4A were the top contributing genes after excluding the previously identified GWAS loci regions. Conclusions Our results from this genetic association study support that T2D, particularly the obesity and lipodystrophy mechanistic clusters, and MODY genomic susceptibility regions play a role in the etiology of PDAC.
A Comprehensive Analysis on the Impact of Hypothermic Machine Perfusion and its Influence on Delayed Graft Function
Li, Zhihao , Mahgoub, Mohammed, Alrifai, Ahmed, Ryan, Randi J. , Issa, Naim , Mahgoub, Mohammed Y, Alrifai, Ahmed Zeen Alabedeen, Cortez, Alexander R. , Li, Zhihao , Smith, Byron H. , Mour, Girish , Jadlowiec, Caroline C. , Riad, Samy

Mayo Clinic

Transplantation Direct | November 7, 2025 | Volume: 11 | Issue: 12 | Pages: e1875

10.1097/txd.0000000000001875 | PMID 41209481 Get It

Background. Delayed graft function (DGF) in deceased-donor kidney transplantation increases morbidity, prolongs hospitalization, and increases healthcare costs. Hypothermic machine perfusion (HMP) has emerged as a promising strategy to reduce DGF; however, large-scale real-world data remain limited. Methods. We performed a retrospective cohort analysis using the Scientific Registry of Transplant Recipients (2014–2024), including adult dialysis-dependent recipients of deceased-donor kidneys preserved using either static cold storage (SCS) or HMP. The primary outcome was DGF, defined as dialysis requirement within 7 d posttransplant. A matched-pairs analysis was conducted using kidneys from the same donor. Results. The overall cohort included 59 859 recipients (46.8% SCS, 53.2% HMP), with 2208 matched pairs identified. In the overall cohort, HMP grafts had longer cold ischemia times and a higher kidney donor risk index. They were more frequently obtained from older and donation after circulatory death donors. Although the overall DGF incidence was higher with HMP (34.4% versus 30.9%, P < 0.001), matched-pairs analysis revealed significantly lower DGF rates with HMP (29.8% versus 36.1%, P < 0.001). Adjusted analyses identified HMP as protective against DGF (overall cohort odds ratio, 0.71; 95% confidence interval, 0.66-0.78; paired cohort OR, 0.68; 95% CI, 0.50-0.93). Additional modifiable risk factors include prolonged cold ischemia time, higher recipient body mass index, and longer dialysis duration. Conclusions. This real-world study demonstrates that HMP is associated with a significant reduction in DGF risk in kidney transplantation compared with SCS, supporting its broader implementation and targeted management of modifiable risk factors.
A Multicenter Double-blind Randomized Sham-controlled Trial Assessing the EndoBarrier Duodenal-jejunal Bypass Liner for the Treatment of Poorly Controlled Type 2 Diabetes Mellitus With Concomitant Obesity
Thompson, Christopher C. , Jirapinyo, Pichamol , Brethauer, Stacy A., Shaheen, Nicholas J. , Sullivan, Shelby , Wilson, Erik B., Schulman, Allison R. , Butsch, W. Scott , Gersin, Keith S., Apovian, Caroline M., Schauer, Philip, McCarty, Thomas R. , Koch, Timothy R. , Dayyeh, Barham K. Abu

Mayo Clinic

Annals of Surgery | November 7, 2025 | Volume: 284 | Issue: 1 | Pages: 34-42

10.1097/sla.0000000000006974 | PMID 41199626 Get It

Objective: An endoscopically placed duodenal-jejunal bypass liner (DJBL) may provide a safe adjunctive therapy for those with poorly controlled type 2 diabetes mellitus (T2DM) and obesity. Background: Although some endoscopic therapies have been shown to improve glycemic indices secondary to weight loss, small bowel interventions may have direct metabolic effects. A meta-analysis of observational studies demonstrated reduction in HbA1c by 1.3% at 1 year after DJBL in patients with T2DM and obesity. Methods: This was a multicenter, double-blind, randomized, sham-controlled trial comparing DJBL to sham procedure with medical management and lifestyle modification. Primary endpoints included mean difference in changes in HbA1c at 12 months between arms, and device-related serious adverse events (SAEs). Secondary endpoints included percent total weight loss (%TWL) and subjects achieving HbA1c≤7% and TWL≥5% at 12 months. Results: Three hundred twenty subjects were randomized to DJBL (n=212) and sham (n=108). Baseline HbA1c and BMI were 8.79±0.92% and 38.45±5.75 kg/m 2 . On modified intent-to-treat analysis, change in HbA1c at 12 months was −1.10±1.45% and −0.28±1.54% for DJBL and sham groups, respectively ( P =0.0004). Rate of device-related SAEs was 9.4% including intolerance (3.7%), hemorrhage (2.8%), and hepatic abscess (2.3% stopping study early). At 12 months, DJBL group experienced greater weight loss compared with sham (7.7±9.6% TWL and 2.1±5.4% TWL, respectively; P <0.0001), with significantly more patients achieving HbA1c ≤ 7% (28.3% vs. 9.4%; P <0.0003) and TWL ≥ 5% (60.4% vs. 21.3%; P <0.0001). Conclusions: DJBL met primary glycemic control efficacy and primary safety endpoints, while providing clinically significant weight loss, and comorbidity improvement.